Cancer dormancy: Opportunities for new therapeutic approaches

Nature Medicine

Volumn 3, Issue 5, 1997, Pages 505-509

  Uhr, Jonathan W ^a   Scheuermann, Richard H ^b   Street, Nancy E ^a   Vitetta, Ellen S ^a  

^a Univ of Texas SW Medical School   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; CANCER VACCINE; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY;

CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; GROWTH INHIBITION; HUMAN; IMMUNE SYSTEM; PRIORITY JOURNAL; REVIEW;

SAXICOLA; SAXICOLA TORQUATA; SAXICOLA TORQUATA AXILLARIS; SAXICOLA TORQUATA RUBICOLA;

EID: 0030915612     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0597-505     Document Type: Review

References (19)

1. Woodruff, M. Interaction of cancer and host [The Walter Hubert Lecture, 1982]. Br. J. Cancer 46, 313-322 (1982).
2. Callaway, M.P. & Briggs, J.C. The incidence of later recurrence (greater than 10 years): An analysis of 536 consecutive cases of cutaneous melanoma, Br. J. Plast. Surg. 42, 46-49 (1989).
3. Henderson, J.C., Harris, J.R., Kinne, D.W. & Hellman, S. Cancer of the breast, in Cancer: Principles and Practice of Oncology, 3rd edn. (eds. DeVita, V.J., Jr., Hellman, S. & Rosenberg, S.A.) 1197-1268 (Lippincott, Philadelphia, 1989).
4. Meeker, T. et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N. Engl. J. Med. 312, 1658-1665 (1985).
5. Ito, Y. & Miyamura, K. Clinical significance of minimal residual disease in leukemia detected by polymerase chain reaction: Is molecular remission a milestone for achieving a cure? Leuk. Lymphoma 16, 57-64 (1994).
6. Israeli, R.S. et al. Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J. Urol. 153, 573-577 (1995).
7. Loric, S. et al. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Clin. Chem. 41, 1698-1704 (1995).
8. Folkman, J. Tumor angiogenesis. in The Molecular Basis of Cancer (eds. Mendelsohn, J., Howley, P.M., Israel, M.A. & Liotta, L.A.) 206-232 (Saunders, Philadelphia, 1995).
9. Bouck, N., Stellmach, V. & Hsu, S.C. How tumors become angiogenic. Adv. Cancer Res. 69, 135-174 (1996).
10. Vaage, J. & Harlos, J.P. Collagen production by macrophages in tumor encapsulation and dormancy. Br. J. Cancer 63, 758-762 (1991).
11. Penn, I. The effect of immunosuppression on pre-existing cancers. Transplantation 55, 742-747 (1993).
12. Greenberg, P.D. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49, 281-355 (1991).
13. Boon, T., Cerottini, J.C., Van den Eynde, B., van der Bruggen, P. & Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12, 337-365 (1994).
14. Kawakami, Y. et al. T-cell recognition of human melanoma antigens. J. Immunother. 14, 88-93 (1993).
15. Eccles, S.A. & Alexander, P. Immunologically-mediated restraint of latent tumour metastases. Nature 257, 52-53 (1975).
16. Wheelock, E.F., Weinhold, K.J. & Levich, J. The tumor dormant state. Adv. Cancer Res. 34, 107-140 (1981).
17. 1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex. J. Immunol. 137, 1376-1382 (1986).
18. 1 leukemia by allogeneic bone marrow transplantation. J. Immunol. 130, 2452-2455 (1983).
19. 1 lymphoma. Cancer Res. 51, 5045S-5053S (1991).